listed. - CINVANTI™ (aprepitant) injectable emulsion

← Back to document page

1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CINVANTITM safely and effectively. See full prescribing information for CINVANTI. CINVANTITM ( aprepitant) injectable emulsion , for intravenous use Initial Approval: 2003 ----------------------------INDICATIONS AND USAGE---------------------------- CINVANTI is a substance P/neurokinin-1 (NK 1) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of: acute and delayed nausea and vomiting associated with initial and repeatcourses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. (1) nausea and vomiting associated with initial and repeat courses ofmoderately emetogenic cancer chemotherapy (MEC).

5 . 5 WARNINGS AND PRECAUTIONS 5.1 Clinically Significant CYP3A4 Drug Interactions Aprepitant is a substrate, weak-to-moderate (dose-dependent) inhibitor, and an inducer of CYP3A4.

  Emulsion